23 September 2020
Fujifilm Toyama Chemical has reported that the Phase III clinical trial of Avigan (favipiravir) has met its primary endpoint of time to negative conversion of detectable SARS-CoV 2 viral RNA in the RT-PCR assays, and to relief of symptoms, in Covid-19 patients with non-severe pneumonia in Japan. Based on the positive data, the company plans to seek approval for the drug to treat Covid-19, expanding its current indication for influenza patients.
The Serum Institute of India has started manufacturing Codagenix’s intranasal, live-attenuated Covid-19 vaccine candidate, CDX-005. With the vaccine expected to enter Phase I trial in the UK by the end of this year, the Serum Institute will commence production for large-scale safety and efficacy studies, as well as to meet vaccine supply demand worldwide.
The Government of Canada has entered into an agreement for the supply of up to 72 million doses of Covid-19 vaccine candidate being developed by Sanofi and GlaxoSmithKline (GSK), starting next year. The country also increased its confirmed order commitment of Moderna’s potential Covid-19 vaccine to 20 million doses, and maintains an option for an additional 36 million doses.
China-based Sinovac Biotech has started Phase III clinical trial of its inactivated Covid-19 vaccine candidate, CoronaVac, in Turkey. The pivotal study will assess the safety and efficacy of the vaccine candidate and is intended to support the licensure of the product in Turkey. With an adaptive design, the trial will recruit volunteers in a step-by-step approach.
The US’ National Institutes of Health (NIH) has expanded the enrolment target for two clinical trials investigating convalescent plasma as a treatment for hospitalised Covid-19 patients. The trials are now expected to recruit approximately 1,000 participants at academic and community-based hospitals across the US.
Pakistan has started Phase III clinical trials of China-based CanSino Biologics’ Covid-19 vaccine candidate, according to a government minister and an official at the company. The trial, being led by the government-run National Institute of Health (NIH) and pharmaceutical company AJM, is set to enrol up to 10,000 in Pakistan.